Zobrazeno 1 - 10
of 238
pro vyhledávání: '"A. Oaknin"'
Autor:
Gabe S. Sonke, Cara Mathews, Carol Aghajanian, Nicoletta Colombo, Alexandra Leary, Ana Oaknin, Joyce F. Liu, Giovanni Scambia, William H. Bradley, Elizabeth S. Lowe, Jae Weon Kim, Alla Lisyanskaya, Antonio González-Martín, Anne Floquet, Michael Friedlander, Kathleen N. Moore, Ralph Bloomfield, Amit M. Oza, Charlie Gourley, Susana Banerjee, Paul DiSilvestro
Publikováno v:
Colombo, N, Moore, K, Scambia, G, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A, González-martín, A, Aghajanian, C, Bradley, W H, Kim, J, Mathews, C, Liu, J, Lowe, E S, Bloomfield, R & Disilvestro, P 2021, ' Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial ', Gynecologic Oncology . https://doi.org/10.1016/j.ygyno.2021.07.016
Scientia
Scientia
Olaparib; Ovarian cancer; Tolerability Olaparib; Cáncer de ovarios; Tolerabilidad Olaparib; Càncer d'ovaris; Tolerabilitat Objectives In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a substantial progression-free survival
Autor:
Kathleen N. Moore, Alexandra Leary, Dominique Berton, Christina P. Opperman, Maria Del Pilar Estevez-Diz, Laurence Gladieff, Marek Ancukiewicz, Anne-Claire Hardy-Bessard, Frédéric Selle, Isabelle Ray-Coquard, Waldo Ortuzar Feliu, Carlos Rojas, Bradley J. Monk, David M. O'Malley, Ana Oaknin, Carla Rameri Alexandre Silva de Azevedo, Leslie M Randall, Jérôme Alexandre
Publikováno v:
Scientia
Cervical cancer; Checkpoint inhibitor; Immunotherapy Cáncer de cuello uterino; Inhibidor de puntos de control; Inmunoterapia Càncer cervical; Inhibidor de punts de control; Immunoteràpia Objective This phase II clinical trial evaluated the safety
Autor:
Ignace Vergote, Laura Vidal, Giovanni Scambia, Vicente Alfaro, Isabelle Ray-Coquard, Stephanie Gaillard, Cristian Fernandez, Carmen Kahatt, Ana Oaknin, Ivor Benjamin, Beatriz Pardo-Burdalo, Rebecca Kristeleit, Nicoletta Colombo, Domenica Lorusso, Patricia Pautier, Miguel Aracil, David M. O'Malley, Zsuzsanna Papai, Antonio Nieto, Ali Zeaiter
Publikováno v:
Gynecologic Oncology. 163:237-245
Objective The randomized phase 3 CORAIL trial evaluated whether lurbinectedin improved progression-free survival (PFS) compared to pegylated liposomal doxorubicin (PLD) or topotecan in patients with platinum-resistant ovarian cancer. Methods Patients
Autor:
I. Vergote, A. González-Martín, I. Ray-Coquard, P. Harter, N. Colombo, P. Pujol, D. Lorusso, M.R. Mirza, B. Brasiuniene, R. Madry, J.D. Brenton, M.G.E.M. Ausems, R. Büttner, D. Lambrechts, M. Ausems, J. Brenton, M. Abreu, S. Balboni, S. Banerjee, M. Barberis, M.P. Barretina Ginesta, J.-F. Baurain, M. Bignami, L. Bjorge, P. Blecharz, I. Bruchim, M. Capilna, N. Cerana, A. Cicchetti, D. Collins, N. Concin, M. D’Incalci, B. Davidson, T. de la Motte Rouge, P. De Iaco, F. Demirkiran, H. Denys, T. Doerk, A. Dorum, A. Ferrero, A.P. Fidalgo, M. Genuardi, L. Gladieff, R. Glasspool, C. Grimm, M. Gultekin, E. Hahnen, A. Hasenburg, A. Hegmane, V. Heinzelmann, E. Hogdall, R. Janavicius, S. Jarmalaite, R. Kalachand, R. Kaneva, S. Kilickap, R. Kocian, D. Kolencik, R. Kristeleit, A. Kryzhanivska, A. Leary, B. Lemley, M. Ligtenberg, J.A. López-Guerrero, C.J. Lord, E. Avall-Lundqvist, J. Maenpaa, S. Mahner, F. Marmé, C. Marth, I. McNeish, S. Merkelbach-Bruse, M. Mourits, N. Normanno, A. Oaknin, K. Ojamaa, C. Papdimitriou, F. Penault-Llorca, A.M. Perrone, S. Pignata, E. Pikarsky, E. Rouleau, M. Rubio, A. Sapino, B. Schmalfeldt, J. Sehouli, R. Shapira, K.D. Steffensen, V. Sukhin, J. Syrios, Z. Szallasi, C. Taskiran, M. Terzic, M. Tischkowitz, I. Toth, K. Van de Vijver, M.A. Vardar, B. Wasag, P. Wimberger, E. Witteveen
Publikováno v:
Annals of Oncology, 33, 3, pp. 276-87
Vergote, I, González-Martín, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M R, Brasiuniene, B, Madry, R, Brenton, J D, Ausems, M G E M, Büttner, R, Lambrechts, D, European experts’ consensus group & Dahl Steffensen, K 2022, ' European experts consensus : BRCA/homologous recombination deficiency testing in first-line ovarian cancer ', Annals of Oncology, vol. 33, no. 3, pp. 276-287 . https://doi.org/10.1016/j.annonc.2021.11.013
ANNALS OF ONCOLOGY
Annals of Oncology, 33, 276-87
Vergote, I, González-Martín, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M R, Brasiuniene, B, Madry, R, Brenton, J D, Ausems, M G E M, Büttner, R, Lambrechts, D, European experts’ consensus group & Dahl Steffensen, K 2022, ' European experts consensus : BRCA/homologous recombination deficiency testing in first-line ovarian cancer ', Annals of Oncology, vol. 33, no. 3, pp. 276-287 . https://doi.org/10.1016/j.annonc.2021.11.013
ANNALS OF ONCOLOGY
Annals of Oncology, 33, 276-87
BACKGROUND: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typicall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048b3ea84583ffb10df0f113446b4777
Autor:
Carol Aghajanian, Lee-may Chen, Scott H. Kaufmann, Amit M. Oza, Geoffrey I. Shapiro, Rebecca Kristeleit, Sandra Goble, Iain A. McNeish, Diane Provencher, Ana Oaknin, Alexandra Leary, Lara Maloney, Elizabeth M. Swisher, Isabelle Ray-Coquard, Howard A. Burris, Stephen Welch, Kevin K. Lin, Tanya Kwan, Ronnie Shapira-Frommer, Anna V. Tinker, David M. O'Malley, Robert L. Coleman
Publikováno v:
Gynecologic Oncology. 163:490-497
Objective. To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. Methods. This post hoc analysis po
Autor:
Keiichi Fujiwara, Robert L. Coleman, Amit M. Oza, Lara Maloney, Frederik Marmé, Bradley J. Monk, Ramez N. Eskander, R Kristeleit, Tamar Safra, Kevin K. Lin, David M. O'Malley, Shannon N. Westin, Nikolay Grechko, Ana Oaknin, Domenica Lorusso, Michelle K. Wilson, Thomas J. Herzog, Danny Shih, Stephanie Hume, Sandra Goble, Iain A. McNeish
Publikováno v:
International Journal of Gynecological Cancer
BackgroundThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maint
Autor:
Giovanni Scambia, Lara Maloney, Domenica Lorusso, Nicoletta Colombo, Margarita Amenedo Gancedo, Robert L. Coleman, Andrew R Clamp, Deborah K. Armstrong, Jeffrey C. Goh, Sandra Goble, Elizabeth M. Swisher, Ana Oaknin, Carol Aghajanian, Johanne I Weberpals, Susana Banerjee, Terri Cameron, Jonathan A. Ledermann, Robert W. Holloway, David M. O'Malley, Andrew Dean, Jesús García-Donas, P.C. Fong, Amit M. Oza, Alexandra Leary
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 20, Pp 7162-7173 (2021)
Scientia
Cancer Medicine, Vol 10, Iss 20, Pp 7162-7173 (2021)
Scientia
Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum‐based chemotherapy and baseline disease. Methods Patients were randomized 2:1 to receive eith
Autor:
Kathleen N. Moore, Amit M. Oza, Conleth G. Murphy, Nicoletta Colombo, Giovanni Scambia, J. Wang, P.C. Lim, Jason A. Konner, Bradley J. Monk, Anna Berkenblit, Michael J. Birrer, Patricia Pautier, H. Hirte, M. Prasad-Hayes, Ana Oaknin, Ignace Vergote, Susana Banerjee, Domenica Lorusso, Janos L. Tanyi, Gottfried E. Konecny
Publikováno v:
Scientia
Chemotherapy; Mirvetuximab soravtansine; Ovarian cancer Quimioterapia; Mirvetuximab soravtansina; Cáncer de ovarios Quimioteràpia; Mirvetuximab soravtansina; Càncer d'ovaris Background Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab500045f9eb68bf0669cf8d0f50c90f
https://lirias.kuleuven.be/handle/20.500.12942/692015
https://lirias.kuleuven.be/handle/20.500.12942/692015
BackgroundUterine serous carcinoma is a distinct histologic subtype of endometrial cancer with an aggressive phenotype, poor prognosis, and limited therapeutic options. A previous proof-of-concept phase II trial of the Wee1 inhibitor adavosertib in u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4fb295d011f9f5f8ff082b09486fbb2
http://hdl.handle.net/10281/346558
http://hdl.handle.net/10281/346558
Autor:
Lea Dutta, Vicky Makker, Melissa Zale, Matthew H. Taylor, Ana Oaknin, David M. O'Malley, Antonio Casado Herraez, Robert Orlowski, Min Ren
Publikováno v:
The Oncologist
Background The combination of lenvatinib plus pembrolizumab has shown efficacy in treatment of advanced endometrial carcinoma (that is not microsatellite instability–high or mismatch repair deficient) following prior systemic therapy in any setting